Multiple myeloma (MM) is still considered as the second most prevalent haematological malignancy and despite recent progresses in treatment options, MM still remains fatal for most patients.
The current project aims at targeting the MM cells by nanobodies. Nanobodies are small single-domain antigen binding entities, raised in camels or llama. As result of their small size, these nanobodies are not immunogenic and are able to penetrate the cancer tissue.
In the current project the idiotype secreted and expressed by the MM cells will be used as antigen for the generation of nanobodies.
The syngeneic murine 5TMM models will be used for this study. Tumor cells will be inoculated into naïve mice and at different time points after injection, labeled antibodies will be administered to the mice and the biodistribution will be imaged. The obtained signals will be compared to those conventionally used to assess tumor burden in the bone marrow including Real Time Quantitative PCR and FACS analysis using anti-idiotype antibodies.
In conclusion, this study will provide evidence of the usefulness of these antibodies in targeting MM cells. If proven usefull, further research will include the search of a common antigen (for different MM patients) and coupling of specific inhibitors to these antigens such as siRNA or toxins, thereby reducing the potential systemic side effects.
Effective start/end date1/01/0931/12/12

    Research areas

  • nanobodies, siRNA, multiple myeloma, 5TMM model

    Flemish discipline codes

  • Basic sciences
  • Biological sciences

ID: 3288287